Results 251 to 260 of about 344,235 (293)
Some of the next articles are maybe not open access.
Killing Mechanisms of Cytotoxic T Lymphocytes
Physiology, 1998Cytotoxic T lymphocytes mediate lysis of target cells by various mechanisms, including exocytosis of lytic proteins (perforin, granzymes) and receptor-ligand binding of Fas/APO molecules. Death of target cells is characterized by either necrosis or apoptosis, depending on the killing mechanism used and on the metabolism of the target cell itself.
Peter, Groscurth, Luis, Filgueira
openaire +2 more sources
Cytotoxic T lymphocytes in herpesvirus infections
Veterinary Immunology and Immunopathology, 1984A. INTRODUCTION B. MEASUREMENT OF CTL AND THEIR DIFFERENTIATION FROM OTHER FORMS OF CYTOTOXICITY 1. The chromium re lease assay 2. S p e c i f i c i t y con t ro l s 3. I d e n t i f i c a t i o n of e f f e c t o r c e l l s w i th a l l o a n t i s e r a 4. Ef fec t of i n h i b i t o r s on CTL 5. Target c e l l s C.
B T, Rouse, D W, Horohov
openaire +2 more sources
Virus-Neuron-Cytotoxic T Lymphocyte Interactions
1995Neurons have evolved unique strategies to evade immune recognition which allow viruses to infect and persist, yet resist attack by antiviral cytotoxic T lymphocytes (CTLs). However, the ability of activated CTLs to percolate through the normal central nervous system (CNS) (Hickey et al.
G F, Rall, M B, Oldstone
openaire +2 more sources
Radiosensitivity of Murine T-Lymphocyte Cytotoxicity
Radiation Research, 1984A biphasic curve was observed when surviving allogeneic lytic activity was plotted as a function of irradiation delivered before sensitization. Flow cytometry analysis demonstrated that the number of cells was reduced in response to increasing dose and that subset precursors Lyt 1+2+ were proportionally more radiosensitive than the other subsets ...
openaire +2 more sources
Cytotoxic T-Lymphocyte–Associated Antigen-4
Clinical Cancer Research, 2007Abstract Previously, the development of immune-based therapies has primarily focused on vaccines and cytokines, yielding benefit in a small percentage of patients. Recent advances in our understanding of the function of costimulatory molecules have revitalized enthusiasm in the development of immune therapies for cancer.
openaire +2 more sources